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Abstract. The formation of distinctive basic FGF- 
heparan sulfate complexes is essential for the binding 
of bFGF to its cognate receptor. In previous experi- 
ments, cell-surface heparan sulfate proteoglycans ex- 
tracted from human lung fibroblasts could not be 
shown to promote high affinity  binding of bFGF when 
added to heparan sulfate--deficient cells that express 
FGF receptor-1 (FGFR1) (Aviezer, D., D. Hecht, M. 
Safran, M. Eisinger, G. David, and A. Yayon. 1994. 
Cell 79:1005-1013).  In alternative tests to establish 
whether cell-surface proteoglycans can support the for- 
mation of the required complexes, K562 cells were first 
transfected with the IIIc splice variant of FGFR1 and 
then transfected with constructs coding for either syn- 
decan-1, syndecan-2, syndecan-4 or glypican, or with an 
antisense syndecan-4 construct. Cells cotransfected 
with receptor and proteoglycan showed a two- to three- 
fold increase in neutral salt-resistant specific 125I-bFGF 
binding in comparison to cells transfected with only re- 
ceptor or cells cotransfected with receptor and anti- 
syndecan-4. Exogenous heparin enhanced the specific 
binding and affinity cross-linking of 125I-bFGF to 
FGFR1 in receptor transfectants that were not cotrans- 
fected with proteoglycan, but had no effect on this 
binding and decreased the yield of bFGFR cross-links 
in cells that were cotransfected with proteoglycan. Re- 
ceptor-transfectant cells showed a decrease in glyco- 
phorin A expression when exposed to bFGF. This sup- 
pression was dose-dependent and obtained at 
significantly  lower concentrations of bFGF in pro- 
teoglycan-cotransfected  cells. Finally, complementary 
cell-free binding assays indicated that the affinity of 
125I-bFGF for an immobilized FGFR1 ectodomain was 
increased threefold when the syndecan-4 ectodomain 
was coimmobilized with receptor. Equimolar amounts 
of soluble syndecan-4 ectodomain, in contrast, had no 
effect on this binding. We conclude that, at least in 
K562 cells, syndecans and glypican can support bFGF- 
FGFR1 interactions and signaling, and that cell-surface 
association may augment their effectiveness. 
T 
HE  signaling  pathways that  are  activated by  the 
binding  of  various  FGFs,  Vascular  Endothelial 
Growth  Factor  (VEGF)  and  Heparin-Binding 
EGF-like growth factor to their cognate receptors have 
been qualified as "heparin dependent." This contention is 
based on the failure of these signaling systems in cells that 
are defective in the synthesis of heparan sulfate (HS) 1 and 
on the ability to restore the activity of these pathways in 
these cells by providing an exogenous source of heparin- 
like  polysaccharide.  In the case  of basic FGF (bFGF or 
FGF-2),  heparin restores the high affinity binding of the 
growth factor to the tyrosine kinase receptor proteins, and 
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restores the biological effects of this growth factor on cell 
differentiation and proliferation (Yayon et al., 1991; Rap- 
raeger et al., 1991). The primary defect in the HS-deficient 
cells appears to be situated at the level of the initiating 
event, with the growth factor failing to occupy a binding 
site on the receptor and to induce a receptor configuration 
that leads  to signaling. Different models that have been 
proposed as explanations for this HS requirement and the 
pharmacological effects of heparin (reviewed by Mason, 
1994)  include:  a  heparin-induced  fit,  whereby  the  gly- 
cosaminoglycan allows the growth factor to adopt a con- 
formation that  is  appropriate  for  receptor  engagement 
(Yayon et al., 1991), the need for HS to participate in the 
formation of a multimolecular signaling complex, whereby 
it binds simultaneously to both ligand and receptor (Nu- 
gent and Edelman, 1992; Kan et al., 1993; Guimond et al., 
1993; Pantoliano et al., 1994), and indirect effects of hep- 
arin on the receptor dimerization that is required for sig- 
naling, by promoting the formation of ligand dimers (Or- 
nitz et al.,  1992; Spivak-Kroizman et al.,  1994). On the 
other hand, these concepts  have also been challenged or 
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increase the affinity of the growth factor for its receptor 
(two- to threefold increase) and heparin or HS were pro- 
posed only to be needed at low concentrations of ligand 
(Roghani et al., 1994). In all models, the direct binding in- 
teractions between the growth factor and heparin-like gly- 
cosaminoglycan are proposed as essential for the activa- 
tion of the signaling pathway. 
bFGF binds preferentially to exon IIIc-containing forms 
of the FGF receptors (FGFRs)  1-3, which are predomi- 
nantly  mesenchymally  expressed  (Dionne  et  al.,  1990; 
Johnson et al., 1991; Keegan et al., 1991; Miki et al., 1992; 
Yayon et al.,  1992; Werner et al.,  1992;  Chellaiah et al., 
1994). In vitro the affinity of bFGF for the IIIc splice vari- 
ant of FGFR1 is increased by about one order of magni- 
tude when heparin is added (Pantoliano et al., 1994), and 
in HS-expressing cells, the affinity of bFGF for the recep- 
tors  (10-1°-10  -11  M)  is  about  two  orders  of magnitude 
higher than the affinity of the growth factor for cell-sur- 
face HS  (10 -8-  10 -9 M)  (Moscatelli, 1987; Wennstrrm et 
al.,  1991).  Clusters  of IdoA(2-OSO3)ctl,4GIcNSO3 units 
have been identified as  bFGF-binding  sequences  in  HS 
chains derived from human skin fibroblasts (Turnbull et 
al.,  1992) and bovine aortic muscle cells (Habuchi et al., 
1992). Heparin-derived penta- or hexasaccharides of simi- 
lar structure effectively bind to bFGF and inhibit bFGF 
binding to cell surface HS proteoglycans (HSPGs), but fail 
to promote FGFR binding (Tyrrell et al., 1993; Maccarana 
et al., 1993).  The minimal structural requirements to en- 
hance bFGF binding to its receptor and to support bFGF- 
induced mitogenesis appear to be realized in a dodecasac- 
charide containing the bFGF-binding site and additional 
6-0 sulfated groups (Ishihara et al., 1993; Guimond et al., 
1993; Walker et al., 1994). 
The ability of cells to generate HS of a defined sequence 
complexity varies during ontogenesis (David et al., 1992a; 
Kato et al.,  1994), and some observations directly imply 
that part of the cellular controls on signaling by FGF-like 
growth factors may occur at the level of the expression of 
the required HS cofactor/receptor sequences (Nurcombe 
et al., 1993). The possibility of PG specificity in this respect 
is supported by the observation that, in vitro, some hep- 
arins and whole PG extracts from human lung fibroblasts 
were able to induce the binding of bFGF to an immobi- 
lized recombinant FGFR-alkaline phosphatase fusion pro- 
tein, whereas some specific PG forms, such as syndecans 1 
and 2, that were purified from these cell extracts were in- 
active and even inhibited the effect of the active heparin 
fraction (Aviezer et al., 1994a). In subsequent studies, the 
major  activating  component  of  these  PG  extracts  was 
identified as perlecan, the large extracellular matrix (base- 
ment membrane) PG (Aviezer et al., 1994b). These obser- 
vations, together with indications that overexpression of 
syndecan-1 inhibits the bFGF-induced growth promotion 
of 3T3 cells (Mali et al., 1993), have lead to the suggestion 
that the local expression of active perlecan and the syner- 
gies  and  balances  between  activating  and  nonactivating 
classes  of PGs  will  determine the  degree  and  extent of 
bFGF-induced cellular responses (Aviezer et al., 1994b). 
Our  investigations were  aimed  at identifying cell sur- 
face-associated HSPGs that might promote bFGF binding 
and receptor activation. Using a cell system in which we 
were  able  to  express  independently the  IIIc variant  of 
FGFR1 and four types of PG (i.e., syndecans 1, 2, 4, and 
glypican), as well as a cell-free system in which we used 
6xHis-tailed  recombinant  forms  of receptor  and  PG  to 
mimic their colocalization at the cell surface, we demon- 
strate that all these cell-surface HSPGs can support the 
bFGF-receptor interaction. 
Materials and Methods 
Plasmid Isolation and Construction 
Clones for bFGF and FGFR1 were isolated from a human embryonic lung 
fibroblast XZAPII phage library using oligolabeled PCR-derived probes 
for bFGF and FGFR1 and standard screening procedures (Sambrook et 
al., 1989). 
The bFGF clones were used as PCR templates. The primer set 5'-GGT- 
GTCGACATCGAAGGTAGACCCGCCTFGCCC  G A G GATG G C- 3' 
and 5'-GGCCTGCAGTCAGCTCITAGCAGACAT-3' used for the am- 
plification reaction (Saiki et al,, 1988)  was designed to introduce unique 
restriction sites flanking the coding sequence and a  Factor Xa cleavage 
site at the amino-terminal end. The PCR products were sequenced using 
an automated fluorescent sequencer (Pharmacia Biotechnology Benelux, 
Roosendaal, The Netherlands) and cloned into the prokaryotic expression 
vector pQE-9 (Qiagen, Chatsworth, CA), which introduces a 6xHis tag at 
the amino-terminal end of the encoded protein. 
One FGFR1 clone, identified as the two Ig-like domain isoform (Ig II/ 
IIIc) (Eisemann et al., 1991), was restricted with PstI to remove 370 bp of 
the 5' untranslated sequence and cloned into the eukaryotic expression 
vector pcDNA/Neo (Invitrogen, Leek, The Netherlands), using the HindIII 
and NotI sites from the multiple cloning sites of the vectors. 
The cDNAs for human syndecan-4 (David et al., 1992b), syndecan-2 
(Marynen et al., 1989), and syndecan-1 (Mali et al., 1990) were cloned into 
the KpnI and NheI sites of the episomal expression vector pREP4 (Invi- 
trogen). The cDNA for glypican (David et al., 1990)  was released with 
HindIII and NotI, and cloned into the corresponding sites of pREP4. A 
630-bp fragment containing the complete coding sequence of syndecan-4 
was antisense cloned into the HindIII and BamHI sites of the same vector. 
Plasmids coding for 6xHis-tagged ectodomains of FGFR1  and synde- 
can-4 were constructed by PCR. A 300-bp fragment of FGFR1 was ampli- 
fied using the primer set 5'-GACCCGCAGCCGCACATCCAGTGG-3' 
and  5'-CCGCTCGAGTCAGTGATGGTGATGGTGATGCTCCAG- 
GTACAGGGGCGAGGTCATCACTGCC-3', digested  with  BfrI  and 
XhoI, and cloned into the corresponding restriction sites of the FGFR1 
plasmid, replacing the sequences that code for the transmembrane and cy- 
toplasmatic  domains.  The  resulting  insert,  FGFRIe,  was  cloned  into 
pMEP4  via HindIIl  and XhoI.  A  sequence coding for  a  6xHis-tagged 
ectodomain of syndecan-4 was constructed using the primers 5'-GCAAT- 
TAACCCTCACTAAAGGG-3' and 5'-CGCGTCGACTCAGTGATG- 
GTGATGGTGATGCTCCGTrCTCTCAAAGATGTFGCrGCCCTGC  - 
3'. The PCR fragment was restricted with Bglll and SalI, and cloned in the 
corresponding sites of the syndecan-4 plasmid. The resulting insert, syn4e, 
was released with SpeI and XhoI, and cloned into the NheI and XhoI sites 
of the  vector pMEP4.  All constructs were  sequenced to  exclude mis- 
matches. 
Purification  and Characterization  of 
Recombinant bFGF 
Nondenaturing purification of the recombinant 6xHis-bFGF was carried 
out according to standard protocols (Seno et al., 1990).  In short, Escheri- 
chia coli M15 containing the appropriate pQE-9 construct plus the repres- 
sor plasmid pREP4 were induced with 1 mM IPTG at an OD of 0.9. Before 
sonication for 3 min on ice in the presence of 10 mM 13-mercaptoethanol, 
the harvested cells were incubated for 1 h at 4°C in 50 mM NaH2PO4, 10 
mM Tris, 300 mM NaC1,  15%  sucrose, 0.1  mg/ml lysozyme, and 1 mM 
PMSF.  After centrifugation, the bacterial  lysate was applied to  an Ni- 
NTA resin column (Qiagen), equilibrated at pH 8.0 (50 mM NaH2PO4, 
300 mM NaC1), and eluted at pH 4.5 (50 mM NaH2PO4, 500 mM NaCI) 
(Hochuli et al., 1987).  After readjustment to pH 8.0,  this eluate was ap- 
plied to Heparin-Ultrogel (IBF Pharmindustrie, Villeneuve-la-Garenne, 
France), washed with 1 M  NaC1,  and eluted with 2 M  NaC1. Total yield 
was ~4 mg purified bFGF per liter of culture (20 g of cells), as determined 
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Tricine-SDS-PAGE (Sch~igger and von Jagow, 1987), and was detectable 
with an anti-bovine bFGF mAb on Western blot. Stimulation of thymi- 
dine incorporation in serum-starved Swiss 3"1"3 fibroblasts, induced with 2 
ng/ml 6xHis-bFGF for 18 h, confirmed the biological activity of this recom- 
binant product. 
Extraction and Purification of Cell-surface PGs 
Cell surface PGs were extracted with a Triton X-100 buffer in the pres- 
ence of proteinase inhibitors, concentrated on a DEAE-Trisacryl M  col- 
umn (IBF Pharmindustry, Villeneuve-la-Garenne, France),  and further 
purified by ion exchange chromatography on MonoQ in Triton-urea-Tris 
buffer (Lories et al., 1987).  [mmunopurification was carried out with core 
protein-specific  mAbs  immobilized  on  CNBr-activated  Sepharose  4B 
(Lories et al., 1989). 
Purification of Recombinant FGFRI and 
Syndecan-4 Ectodomains 
Recombinant 6xHis-tagged ectodomains of FGFR1 (FGFRle) and synde- 
can-4 (Syn4e) were isolated from the conditioned culture media of K562 
cells that were transfected with the corresponding episomal plasmid con- 
structs. Serum-free media from pMEP4-transfected cells were harvested 
12-16 h  after induction with 5 I~M CdC12. FGFRle was purified by two 
consecutive absorptions on Ni-NTA resin (see above). Syn4e was first ab- 
sorbed on DEAE-Trisacryl M and then purified by metal chelate chroma- 
tography. The final eluates were concentrated by ultrafiltration (Centri- 
con  30;  Amicon, Inc.,  Beverly,  MA),  and  the  quantity  (~400  ILg/liter 
medium) and  purity  (>90%)  of the product  were  estimated by  SDS- 
PAGE. 
Western Blotting 
Heparitinase and chondroitinase ABC-digested PG were fractionated by 
SDS-PAGE and blotted on Z probe membranes. The blots were first in- 
cubated with the designated mAbs, and then with alkaline phosphatase- 
conjugated second antibodies, and finally developed with AMPPD (Tropix, 
Bedford, MA) for chemiluminescence and autoradiography. 
Analysis of the GAG Compositions 
Free glycosaminoglycan  side chains were obtained by proteinase K diges- 
tion  of purified 3sso3-1abeled PGs. The GAG chains were  either sub- 
jected to the low pH nitrous acid procedure (Shively and Conrad, 1976) or 
digested with chondroitinase ABC. Both preparations and an untreated 
control  were precipitated  with cetyl pyridinium chloride  and then col- 
lected on glass filter papers. The HS content was calculated as (cpm~nu~t~d 
-  cpmrlNO2/Cpmuntreated), the chrondroitin sulfate (CS) content was calcu- 
lated  as  (epmuntreate  d  -  CpmABCase[Cpmuntreated). All  analyses were  per- 
formed in duplicates. 
Affinity Chromatography of HSPG on Chelate 
Complex-bound bFGF 
Purified 6xHis-bFGF was reapplied to an Ni-NTA column at a concentra- 
tion  of  50--100  p,g/ml  gel  (~1/100  of  the  maximal binding  capacity), 
washed with assay buffer (50 mM Na2HPO4, pH 7.5, 0.1% Triton X-100, 
20 p~g/ml BSA) and increasing NaC1 concentrations (0-2 M), and reequili- 
brated with assay buffer. No bFGF leakage could be detected during the 
wash. Immunopurified HSPGs were dialyzed against the assay buffer and 
applied to aliquots of bFGF-Ni-NTA resin. Bound HSPGs were eluted 
with a  NaC1 step gradient (0-2 M). Every chromatographic experiment 
was repeated at least once, with similar results. 
Cell Transfections 
K562 cells (ATCC CCL 243) were routinely grown in DME F12 medium 
supplemented with  10%  FCS  and  L-glutamine. For  transfection, K562 
cells were prewashed with Ca  + +- and Mg  + +-free PBS and incubated for 10 
min at 4°C (107 cells/ml Ca/Mg-free PBS) with 30 ~g linearized FGFR1- 
pcDNA/Neo, or pcDNA/Neo, before electroporation at 240 V and 960 p,F 
with a gene pulser (Bio Rad Laboratories, Richmond, CA). Selection was 
started 48 h later with 500 p,g/ml G418. Stable transfection was achieved af- 
ter 12 d, and subclones were established by two consecutive limited dilu- 
tion  procedures.  Individual clones were  characterized  for  specific 12sI- 
bFGF binding. The tfansfections with the episomal replicons pREP4[-], 
pREP4[Synl],  pREP4[Syn2],  pREP4[GIyp],  pREP4[Syn4],  and pREP4 
[antiSyn4] were performed in similar ways. Selection with 200 p~g/ml of 
hygromycin over 2 wk resulted in stable cell populations that were not fur- 
ther subcloned. 
125  I-bFGF-binding Assays 
Iodinated bFGF (specific activity =  800-1,200 Ci/mmol) was purchased 
from New England Nuclear (Boston, MA), aliquoted directly upon ar- 
rival, and stored at -70°C. For the cellular binding assays the K562 trans- 
feetants were grown for 72 h in a serum-free medium (DME F12) contain- 
ing 1 g/liter BSA, 8 mg/1 transferfin, and 4 mg/l of insulin, or in Ham's F12 
medium supplemented with 30 mM NaC103 (to suppress the sulfation of 
the GAG chains) and the same additives. Samples of 200,000 cells were in- 
cubated for 90 rain at 4°C in 200 pd DME F12 supplemented with 1 mg/ml 
BSA, 25 mM Hepes, pH 7.5,  and 10 ng/ml 125I-bFGF,  in the absence or 
presence of 1 p.g/ml unlabeled bFGF and with or without 100 ng/ml hep- 
arin. The cells were then washed two times with cold PBS and once with 
2 M NaCI, 50 mM NaHzPO4, pH 7.5. The radioactivities of the salt washes 
and the cell pellets were counted separately. The values obtained in the 
presence of 100-fold excess of unlabeled bFGF were considered unspecific 
binding and were  substracted from the total  counts, The data  are dis- 
played as the means and SDs of three independent experiments. 
In the cell-free binding assay, increasing amounts of 12SI-bFGF were 
combined with FGFRle (6 ng) in the presence or absence of Syn4e (0.8 
ng), trypsinized Syn4e (0.8 rig), or heparin (100 ng/ml), in 500 p~l of assay 
buffer (50 mM NaH2PO4, pH 7.5,  150  mM NaC1, 2  mg/ml gelatin, and 
0.5% Tween 20). Control mixtures consisted of increasing lzSI-bFGF or 
I~I-bFGF and heparin concentrations in assay buffer. All mixtures were 
supplemented with  20  ixl of Ni-NTA  resin  and  incubated  on  a  roller 
shaker at room temperature for 2 h. Bound label was recovered by centrif- 
ugation, washing of the beads in PBS, and discarding of the supernatant. 
Specific ~25I-bFGF binding was measured by substracting the amounts of 
label bound in control mixtures from the counts associated with the beads 
in test mixtures. This experiment was carried out three times with two dif- 
ferent batches of 125I-bFGF. The data were transformed into concentra- 
tion equivalents and analyzed as Scatchard plots (Scatchard, 1949) using a 
computer program for linear curve fitting. 
Covalent Cross-linking of u5I-bFGF to FGFR1 
Wild-type K562 cells and FGFRl-transfected K562 cells were prepared and 
incubated with lZSl-bFGF,  as in the other  bFGF-binding studies. After 
washing with 2 x  1 ml of cold PBS, the cells were incubated with 100 ~g/ 
ml (0.27  mM) disuceinimidyl suberate (Pierce, Rockford, IL) in PBS at 
15°C for 45 min. The reaction was quenched with 20 mM Tris, pH 7.4, in 
PBS. The cell samples were boiled for 5 min in 2% SDS, 10% glycerol, 20 
mM Tris pH 6.8, 1 mM EDTA, and 0.005% bromophenol blue, and were 
applied on 6-20% polyacrylamide gradient gels. After running, the gels 
were stained with Coomassie brilliant blue and dried for autoradiography. 
Quantitative analysis of the intensity of the bFGF-FGFR1 band was per- 
formed with an ImageQuant personal densitometer (Molecular Dynam- 
ics, Sunnyvale, CA). Reference bands in the Coomassie-stained gels were 
also measured to exclude differences in loading. 
Immunofluorescence Cytometry 
Immunocytofluorometry was performed with a FACSort  ® (Becton Dickin- 
son &  Co., Mountain View, CA), and data were analyzed with the pro- 
gram Lysis If. For indirect immunofluorescence staining, K562 cells were 
incubated with the designated mouse mAbs at a concentration of 10 I~g/ml 
for 30 min, washed 2×, and then incubated with FITC-labeled goat anti- 
mouse Ab  (Nordic  Immunology, E1  toro,  CA).  Nonreactive,  isotyped- 
matched mouse mAbs were used to measure background fluorescence. 
FITC-labeled anti-glycophorin A  (GpA) mAb (clone JC159; Dako Glos- 
trup,  Denmark)  and  R-phycoerythrin-labeled  anti-CD14  mAb  (clone 
T!SIK4; Dako) were incubated together and used at the concentration pro- 
posed by the manufacturer. Background was determined with correspond- 
ingly labeled isotyped-matched mAbs (Dual Colour Reagent; Dako). The 
relative mean fluorescence intensity (rMFI) for GpA was calculated as: 
MFlopA-t~ated cells -- MFlbackground treated cells 
GpA rMFi  = 
-  MFI  b  MFlopA-unrreated  cells  ackgmund untreated ceils 
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with the integratable vector pcDNA/Neo containing  an FGFR1 
eDNA or no insert. Two stable subclones, referred to as clone R 
for the FGFR1 transfection and clone V for the vector transfee- 
tion, were then transfected with the episomal vector pREP4, ei- 
ther as such or provided with eDNAs coding for syndecans 4, 2, 1, 
or glypican  (R-0, R-Syn4, R-Syn2, R-Glyp, R-Synl, and corre- 
sponding  V cells). In addition,  clone R was transfected with an 
antisense  syndecan-4  construct  (R-antiSyn4  cells). The cotrans- 
fection  was realized using  the two different selection  markers, 
G418 for pcDNA/Neo and hygromycin for pREP4. 
All experiments were performed at least twice; SEM for all MFI values 
was <4%. 
Results 
Cell-surface PG Expression in K562 Cells 
The transfection  strategy that  was  adopted  to  study the 
FGFR system is illustrated in Fig. 1. Wild-type K562 cells, 
which do not bind bFGF in specific ways (Partanen et al., 
1991), lack any transcriptional message for FGFR1 (Arm- 
strong et al., 1992; our own unpublished data), and express 
only low levels of cell-surface HS  (see below), were first 
transfected with an integratable pcDNA/Neo vector pro- 
vided with eDNA for FGFRI(IIIc) or without insert. One 
Figure 2.  HSPG expression  in K562 cells. Triton X-100 extracts 
of transfected K562, normalized for cell number, were purified by 
ion exchange  chromatography and fractionated by SDS-PAGE 
after digestion  with  heparitinase.  The Western blot was devel- 
oped with mAb 3G10, which recognizes the terminal desaturated 
glucuronate  that caps the HS stubs  after heparitinase digestion, 
to detect all proteins substituted  with HS, and as an assessment of 
the number of HS chains that were expressed. Detection was per- 
formed by chemiluminescence.  Film exposure was given  1 min 
(first six lanes)  or 5 min (last two lanes).  PG-transfected K562 
populations  expressed high numbers of HS chains, which were 
readily detected after 1 rain of exposure, on a single core protein. 
HS expression was barely detectable in wild-type and R-0 cells af- 
ter 1 min, but bands of 120 kD, 50 kD, and mostly 35 kD were vis- 
ible after the longer exposure.  The stronger 35-kD band in these 
cells reacted with the syndecan-4-specific  mAb 8G3 (not shown). 
stable  subclone  from  the  receptor  transfection  that 
showed specific binding of 125I-bFGF (further referred to 
as clone R) and one subclone from the control transfection 
(further referred to as clone V) were then further trans- 
fected with the episomal vector pREP4, either as such or 
provided with cDNA inserts coding for syndecans 4, 2, 1, 
or  glypican  to  enhance  the  levels  of HS  in  these  cells. 
Clone R  was also transfected with a syndecan-4 antisense 
construct, since this syndecan seems to account (at least in 
part) for the small amounts of endogenous HS expressed 
by K562 cells. Several approaches were then used to evalu- 
ate the effect of these  transfections on the  expression of 
HS by K562 cells. 
After heparitinase digestion, any protein that is substi- 
tuted with HS can be traced by mAb 3G10, since this anti- 
body recognizes the A-glucuronate that caps the HS stubs 
(David et al., 1992a). In Western blots of PG extracts, this 
antibody detected several weak bands in wild-type and in 
R-0 cells  (mainly ~35-kD  bands  visible after more  pro- 
longed exposures), and strong ~35-, 48-, 64-, and 85-kD 
bands in the R-Syn4, R-Syn2, R-Glyp, and R-Synl trans- 
fectants, respectively (Fig.  2).  These proteins were posi- 
tively identified as the expected transfectant proteins with 
the  core  protein-specific mAbs 8G3  (syndecan-4),  10H4/ 
6G12  (syndecan-2),  S1  (glypican), and  2E9  (syndecan-1) 
(not shown). 
Analysis of the amount of HS expressed at the surface 
of the  transfectants,  by quantitative immunofluorescence 
flow cytometry using the HS-specific mAb 10E4 (David et 
al., 1992a), revealed marked (5-10-fold) increases in cell- 
surface HS in all R-PG transfected cell populations (Fig. 3, 
a and b). The expression of the 10E4 epitope at the surface 
of R  antisense  transfectants,  in contrast, was reduced by 
,--~50% in comparison with R-0 cells (Fig. 3 c). Similar anal- 
yses with  protein-specific antibodies  confirmed  the  cell- 
surface expression of the transfectant PGs in transfectant 
cells, the cell-surface expression of endogenous syndecan-4 
in wild-type cells, a  >10-fold increase of the cell-surface 
expression of the syndecan-4 core protein in R-Syn4 cells, 
and the decrease (by 80%) of the cell-surface expression 
of this syndecan in the syndecan-4 antisense transfectants 
(not shown). Very similar PG expressions were also achieved 
in V-PG cotransfection experiments (data not shown). 
All R transfectants were also metabolically labeled with 
[35S]sulfate  for 24 h. PG was extracted from the cells with 
Triton X-100,  and then further purified by ion exchange 
chromatography on DEAE and MonoQ, as shown for the 
R-0 and the R-Syn4 transfectants in Fig. 4 a. Extracts from 
R-PG cells yielded two to fourfold more label per cell than 
the R-0 cell extract. The amount of [35S]syndecan-4 recov- 
ered  by immunoprecipitation  from R-Synl,  R-Syn2,  or 
R-Glyp extracts, in contrast, was identical or slightly lower 
than  the  amount  of [35S]syndecan-4  recovered from R-0 
cells (not shown). Both the R-PG and R-0 materials eluted 
as a  broad early peak (0.45-0.65  M; peak A) and a  more 
distinct later peak (0.70--0.85  M, peak B). All PG transfec- 
tions lead to increases in both peak A and B materials, but 
the  A/B  peak ratio  was  always higher  in  R-PG extracts 
than in the R-0 extract. Qualitatively similar elution pro- 
files were  obtained for immunopurified PG  (not  shown). 
Endogenous  syndecan-4  immunopurified  from R-0  cells 
mimicked  the  profile  obtained  for  the  total  PG  extract 
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Figure 3.  Cell-surface  expression  of HS in K562 cells. Cell-sur- 
face HS was measured by quantitative immunofluorescence cy- 
tometry using the HS-specific mAb 10E4. The background fluo- 
rescent signal (solid line) and the cell-surface HS expression in R-0 
cells (dotted line), R-Synl cells (narrow dotted line), and R-Syn2 
cells (dashed line)• (b) The background fluorescence  and the cell- 
surface  HS expression  in R-0 cells, R-Glyp (narrow dotted line), 
and R-Syn4 (dashed line) cells• (c) The background fluorescence 
and  cell-surface  HS  expression  in  R-0  cells  (dotted  line)  and 
R-antiSyn4 cells (dashed line)• 
from these cells (prominent B peak), whereas the recom- 
binant  PGs  and  also the  endogenous  syndecan-4 immu- 
nopurified from R-PG cells eluted like total R-PG extracts 
(more prominent A peak). 
Early (A peak) and late (B peak) eluting materials from 
total extracts were collected as separate pools and used for 
the  further  immunopurification  of  endogenous  and/or 
transfectant  PG  on  the  corresponding  antibody•  Similar 
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Figure 4.  Ion exchange chromatography of the K562 PGs. 35S-labeled 
PGs produced by the various transfectants were extracted with 
detergent and  subjected  to ion  exchange  chromatography. (a) 
The MonoQ elution profiles obtained for the total extracts from 
the R-0  and  the  R-Syn4 transfectant•  The elution profiles ob- 
tained for the other PG transfectants were qualitatively similar to 
the one obtained for R-Syn4. The profile obtained for the R-anti- 
Syn4 transfectant was similar to that obtained for R-0 cells• (b) 
The elution profiles obtained for the endogenous syndecan-4 im- 
munopurified  from R-0  and  R-Syn2  cells  after digestion  with 
chondroitinase  ABC to remove the CS-substituted  forms. 
pools were also made for the eluted immunopurified PGs. 
Analysis of the GAG chain compositions of these immu- 
nopurified PGs revealed that the syndecans 1, 2, and 4 iso- 
lated from the corresponding transfections contained [35S]HS 
as well as  [35S]CS. This was observed for both A  and B 
peak-derived PGs (with a tendency for a higher HS con- 
tent in B  peak than in A  peak materials, 40-60%  versus 
20-50%). This was also the case for the endogenous syn- 
decan-4 expressed by R-0 cells. Glypican isolated from ei- 
ther the A  or the B  peak of the R-Glyp extract,  on the 
other hand,  carried  almost exclusively HS  (>90%)•  The 
fractionation of intact, heparitinase-, chondroitinase-, and 
doubly  digested  immunopurified  PG  samples  by  SDS- 
PAGE analysis and Western blotting indicated that in all 
instances (except for syndecan-1), the HS and CS chains 
were present on separate coreprotein populations, with lit- 
tle evidence for hybrid PG (shown for syndecan-4 from 
R-Syn4 extracts in Fig. 5). 
Gel filtration chromatography indicated that the sizes of 
the  protein-free  HS  chains  were  nearly  invariant  (~-,14 
kD), whether isolated from different immunopurified PGs 
or from peak A  or B materials (not shown)• Ion exchange 
chromatography indicated that protein-free HS chains de- 
rived from A  peaks were less anionic than chains derived 
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dried  syndecan-4  derived from the  corresponding transfectant 
(R-Syn4) was left untreated (-) or subjected  (+) to heparitinase 
(Hase),  chondroitinase  ABC (Case), or both enzymes.  The di- 
gests were fractionated by SDS-PAGE, blotted, and incubated 
with the syndecan-4 core protein-specific mAb 8G3 or the anti- 
A-HS mAb 3G10. Comparison of the banding patterns after com- 
bined and single enzyme digestions indicated  that the majority of 
syndecan-4  molecules  were substituted  with  HS and a  smaller 
proportion were substituted  with  CS, with little  or no evidence 
for hybrid molecules. Similar results were obtained for the synde- 
can-2. Syndecan-1 materials contained higher amounts of CS, in 
part  as  true  hybrids.  Glypican  carried  almost  exclusively  HS 
chains. 
from B  peaks, but no differences in charge density were 
observed between  HS  chains  from corresponding  peaks 
derived from different PGs (not shown). Finally, sizing of 
the  different  immunopurified  cell-surface  PGs  by  SDS- 
PAGE (after a treatment with chondroitinase ABC to re- 
move the  CS-substituted  forms) indicated  that  the  more 
anionic forms of each HSPG species (B peak) were signifi- 
cantly more retarded than the less anionic forms (A peak). 
Yet,  after heparitinase,  A  and  B  peak PGs yielded core 
proteins of similar sizes, indicating increasing numbers of 
HS-side chains per core protein in the more anionic PGs 
(not shown). 
In another series of experiments, the 35S-labeled R-0 and 
R-PG transfected cells were surface biotinylated immedi- 
ately before the detergent extraction, subjected to ion ex- 
change chromatography, and PG was immunopurified as 
described above. Early (A peak) and late (B peak) eluting 
fractions of each PG were then incubated with streptavi- 
din  beads  to  isolate  the  surface-exposed forms of these 
PGs. The percentage of streptavidin-bound label did not 
differ among A  and B fractions, indicating that the various 
forms of a particular PG were equally well represented on 
the  cell surface. This percentage ranged from 60 to 80% 
for syndecans or glypican isolated from the corresponding 
PG-transfected cells, but was only ~30%  for syndecan-4 
isolated from R-0 cells (data not shown). From the total la- 
bel, the HS content, and the size of the biotinylated frac- 
tion, it was calculated that the PG transfections resulted in 
five- to sevenfold increases in cell surface [35S]HSPG. 
Altogether,  these  data  demonstrated  that  overexpres- 
sion  of  various  cell-surface  PGs  in  K562  cells  lead  to 
marked enhancements in cell-surface HS expression. This 
enhancement was most pronounced for the lesser sulfated 
forms of this glycosaminoglycan that were present on PGs 
Figure 6.  K562 PG binding to immobilized bFGF. Immunopuri- 
fled, 35S-labeled PGs isolated  from peak A and peak B fractions 
(see Fig. 4) were applied to a bFGF column and eluted with a salt 
step gradient (up to 2 M NaCI). Glypican eluted as nearly one 
peak (at 1.2 M), the syndecans eluted as two major peaks, one at 
0.3 M  and a  second  at  1.2 M NaC1. The low salt  eluates (fall 
through,  0.1, 0.3, and 0.6 M) contained ~70% CS, and the high 
salt eluates (0.9, 1.2, 1.5, and 2 M) contained ~90% HS. 
of low chain valency, and it occurred at the detriment of 
the glycanation of the endogenous cell-surface PG (lower 
average HS sulfation  and chain valency). The latter was 
confirmed by the immunopurification of endogenous syn- 
decan-4 from R-0 and R-PG cells, digestion of the PG with 
chondroitinase  ABC,  and  analysis of the  HS-substituted 
syndecan-4 by ion exchange chromatography over MonoQ 
(Fig. 4 b). These findings indicated that the effects of the 
transfections on HS and HSPG synthesis were not simply 
additive, but also competitive, somewhat analogous to the 
effect of 13-xylosides  on the synthesis of CS (stimulation) 
and CSPG (inhibition) by cells. They also underscored the 
conclusion that the gain in cell-surface HS in the transfec- 
tants is driven by the transfectant PG. 
Cell-surface PGs from K562 Cells Bind bFGF 
To evaluate the bFGF-binding properties of the cell sur- 
face  PGs,  the  various  forms were  immunopurified  from 
the corresponding R-PG transfectants and allowed to bind 
to biologically active recombinant bFGF that was immobi- 
lized on Ni-NTA agarose via an aminoterminal 6xHis-tag. 
After equilibration,  the column was eluted  with an NaC1 
step gradient  (Fig.  6).  Syndecans  (isolated from A  or B 
peaks) eluted as two major peaks, one at 0.3 M and a sec- 
ond at 1.2 M NaCI. Analysis of the GAG compositions of 
the eluted syndecan fractions indicated that the pool of the 
first four fractions (nonbound,  and eluting ~<0.6 M  NaC1) 
contained  mainly CS  (~70%),  whereas  the  pool of the 
four last fractions (eluting ~>0.9 M) contained almost ex- 
clusively HS  chains  (N90%).  Glypican,  which  contained 
only HS, eluted as nearly one peak at 1.2 M  NaC1.  These 
data indicate that only HS-carrying forms of the PGs bind 
significantly to bFGF, and they confirm that most synde- 
can cores expressed in K562 cells display either HS or CS 
chains rather than a combination of both. 
Heparin Sensitivity of  the Binding of  bFGF to FGFRI in 
K562 Cells 
We then  measured the  binding of 1251-bFGF to PG- and 
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200,000 cells each, were incubated with 10 ng/ml of 125I-bFGF  for 
90 min at 4°C in the absence or presence of 1 }xg/ml  of unlabeled 
bFGF and with or without  100 ng/ml of heparin.  The bars indi- 
cate the amounts  of iodinated  bFGF that remained specifically 
bound after a neutral 2-M NaC1 wash of the cells. Results  are 
shown for receptor-transfected cells (a), chlorate-treated, recep- 
tor-transfectant cells (b), and for non-receptor-transfected cells 
(c). The values  for receptor-transfectant cells are given as the 
means and SDs of three independent experiments. 
non-PG-transfected V and R cells, as well as the effect of 
exogenous  heparin  on  this  binding  (see  Materials  and 
Methods). Compared to non-PG transfectants, the V-PG 
and the R-PG transfectants showed similar (near 10-fold) 
increases in label in the neutral salt washes of the cells, and 
this label could barely be displaced by a 100-fold excess of 
unlabeled  bFGF  (not  shown).  All  R-PG  transfectants 
showed an increase in specific salt-resistant binding of 1251- 
bFGF when compared with the R-0 and the R-antiSyn4 trans- 
fectants (Fig. 7 a). Adding soluble heparin at a concentra- 
tion of 100 ng/ml doubled specific bFGF binding to RO cells 
and tripled specific bFGF binding to R-antiSyn4 cells,  but 
had no effect on specific bFGF binding by the R-PG trans- 
fectant cells (Fig. 7 a). The specific bFGF binding in the 
presence of heparin was roughly constant  for all R  cell 
populations (excluding differences in the number of FGFR1 
receptors per cell among the various transfectants), and 
was calculated to correspond to ,'-~30,000 binding sites per 
cell. Chlorate treatment of all R transfectant cell populations 
resulted in a decrease of the specific binding to 15-25% of 
the value obtained in the presence of 100 ng/ml of heparin 
(Fig. 7 b). Neither wild-type K562 cells nor any of the PG 
transfectants of the V clone revealed significant levels of 
specific 125I-bFGF  binding,  demonstrating that  the assay 
was measuring FGFRl-related bFGF binding only (Fig. 7 c). 
Heparin Sensitivity of the Affinity Cross-linking of 
bFGF to FGFR1 in K562 Cells 
The participation of the cell-surface HS in the bFGF-recep- 
tor interaction was also investigated by affinity cross-link- 
ing experiments. Covalent cross-linking of 125I-bFGF to the 
various  R-transfectants  demonstrated  a  putative  bFGF- 
FGFR1 complex with an apparent molecular mass of ~140 
kD. The formation of this labeled complex was inhibited 
by adding an excess of cold bFGF, and it did not occur in 
wild-type K562 cells.  Quantitative densitometric analysis 
of the bFGF-FGFR1  complexes in the various transfec- 
tants, formed in the presence and in the absence of exoge- 
nous heparin, gave the following results: 100 ng/ml of hep- 
arin increased the  yield of labeled  bFGFR  cross-links  by 
26%  for R-0,  by 40%  for R-antiSyn4,  and  eightfold for 
chlorate-treated R-0 cells; the same heparin concentration 
decreased ligand cross-linking by 33% for R-Syn4, 46% for 
R-Syn2, 58% for R-Glyp, and 23% for R-Synl (Fig. 8). In- 
creased  yields  of  specific  growth  factor-receptor  com- 
plexes in  non-PG transfectants  and  sulfate-starved cells 
when heparin was added, were consistent with the results 
from the  binding  experiments  that  had  revealed an  en- 
hancement of the bFGF-FGFR1 interaction by heparin in 
these cells (Fig. 7). Negative effects of heparin on the yield 
of growth factor-receptor cross-links in PG transfectants, 
where  heparin  did  not  affect the  extent  of the  specific 
binding of the growth factor (Fig. 7), suggested modal dif- 
ferences  between  heparin-  and  PG-mediated  specific 
bFGF-FGFR1 interactions. 
FGFRI and HS Dependency of the bFGF-induced 
Block in Erythroid Differentiation ofK562 Cells 
K562 cells are multipotential malignant hematopoietic cells 
that spontaneously differentiate into recognizable progen- 
itors of the erythrocytic, granulocytic, and monocytic se- 
ries. A treatment with hemin or the tyrosine kinase inhibitor 
herbimycin A reduces the intracellular tyrosine phosphor- 
ylation in K562 cells and stimulates their erythroid differ- 
entiation  (Richardson  et al.,  1987;  Honma et al.,  1989). 
Exposure of K562 cells to 10  -9 M PMA, in contrast, results 
in  a  reduced  expression  of  erythroid-specific proteins, 
along with a  weak myelomonocytic induction  (Papayan- 
nopoulou  et  al.,  1983).  Erythroid  differentiation of the 
K562 transfectants in  the presence of growth factor was 
therefore measured as  a  test for the functionality of the 
FGFR1 and to evaluate the possible contributions of cell- 
surface PG in receptor-mediated growth factor effects. 
For  these  experiments,  PG-  and  receptor-transfected 
K562 cells were grown in  a  defined serum-free medium 
(see Materials and Methods). After 72 h of growth under 
these  conditions,  bFGF was  added  in  concentrations of 
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bFGF  to  FGFR1  in  K562 
cells. For affinity  cross-link- 
ing, the various  cell popula- 
tions  were  incubated  with 
12SI-bFGF,  following  the 
same  procedures  as  de- 
scribed  in the legend to Fig. 
7. After washing off free la- 
bel,  cell-bound  bFGF  was 
cross-linked  with  0.27 mM 
freshly  dissolved  DSS.  The 
cells were then boiled in SDS 
buffer and fractionated by SDS-PAGE. After autoradiography, the intensities  of the ~140-kD bFGF-FGFR1 bands were measured 
with a densitometer. 100-fold excess of unlabeled bFGF eliminated  the formation of a labeled bFGF-FGFR1 complex in all receptor- 
transfected cells. Heparin potentiated receptor cross-linking in non-PG-transfected populations (by 26% in R-0 cells, by 40% for 
R-antiSyn4 cells) and most strikingly in chlorate-treated R-0 cells (eightfold increase). Wild-type K562 cells lacked any specific recep- 
tor cross-linked band. Heparin, on the other hand, decreased the cross-linking of ligand to the receptor in the PG-transfected cell pop- 
ulations (by 33% for R-Syn4, 46% for R-Syn2, 58% for R-Glyp, and 23% for R-Synl). 
0.5-10 ng/ml, and 72 h  later, the GpA and CD14 expres- 
sions were measured by immunofluorescence flow cytom- 
etry. A  dose-dependent suppression of GpA was obtained 
in all these cells (Fig. 9 a). At the high concentration of 10 
ng/ml of bFGF, the mean GpA level in all R transfectants 
was suppressed to approximately one third of the control 
value (without bFGF), but at lower bFGF concentrations, 
the PG-transfected R cells were more responsive than the 
R-0 and the R-antiSyn4 cells. At a bFGF concentration of 
10 ng/ml, the CD14 expression was increased by ~50% for 
all six R transfectants (data not shown). When treated with 
chlorate, the same cell populations were nearly unrespon- 
sive to bFGF, but the effect of bFGF on the GpA expres- 
sion could largely be restored by the addition of heparin 
(Fig. 9 b). Neither wild-type K562 cells nor any V transfec- 
tant showed a  change in GpA or CD14 expression when 
exposed to bFGF, with or without heparin (Fig. 9 c). Yet, 
these cells and the R  cell populations showed similar de- 
creases in GpA expression in response to 10  -9 M PMA af- 
ter 72 h  (shown only for wild-type cells in Fig. 9 c). The 
interpretation that stimulation of FGFR1 increased intra- 
cellular tyrosine phosphorylation and consequently blocked 
erythroid  differentiation  was supported by the  reverting 
effect of tyrosine kinase inhibitors.  In R  cells that  were 
preincubated with 30 p~M of genistein for 2  h  before the 
addition of 10 ng/ml of bFGF, the GpA and CD14 expres- 
sions remained largely unchanged (data not shown). 
Binding of bFGF to Surface-bound FGFR1 and 
HSPG Ectodomains 
Finally, to exclude possible contributions by non transfec- 
tant PGs or other membrane-anchored molecules, we also 
measured the effect of HSPG on the binding of bFGF to 
its  receptor  under  cell-free conditions.  In this  assay, we 
used  recombinant  FGFRle  and  Syn4e  provided  with 
COOH-terminal  6xHis  tags  that  bind  with  high  affinity 
(K  d =  10  -13)  (Hochuli  et  al.,  1987)  to  Ni-loaded  beads 
(Fig. 10 a). The affinity of bFGF for the ectodomains was 
calculated from the label coprecipitated with the Ni-NTA 
beads versus the free label at various bFGF concentrations 
(Fig. 10 b). The dissociation constant for the interaction of 
bFGF with Syn4e in the absence of FGFRle was 2.7  nM 
(not shown). The calculated dissociation constant for the 
direct bFGF-FGFRle  interaction  in  the  absence  of any 
source of HS  in  this  assay was  1.8  nM,  threefold higher 
than the dissociation constant for the interaction of bFGF 
with the combination of FGFRle and Syn4e (0.6 nM) or 
the  combination  of FGFRle  and  chondroitinase  ABC- 
treated  Syn4e  (not  shown).  In  contrast,  the  affinity  of 
bFGF for the combination of FGFRle and heparitinase- 
treated Syn4e was identical to its affinity for FGFRle. The 
addition  of soluble heparin (100 ng/ml) to bFGF slightly 
increased the affinity of the growth factor for FGFRle (Kd 
=  1.1 nM), whereas trypsin-treated Syn4e added at similar 
concentrations as Syn4e had no effect on the binding (K  d 
=  1.7  nM).  For the combination of FGFRle  and Syn4e, 
the  concentrations  of the ectodomains were chosen such 
that the maximal number of bFGF-binding sites contrib- 
uted by each component were individually similar. Yet the 
maximal number of binding sites obtained for the combi- 
nation of FGFRle and Syn4e did not differ from the maximal 
number of binding  sites obtained for these  ectodomains 
tested individually. This suggested a simultaneous binding 
of bFGF to both ectodomains, as a  ternary complex that 
has greater stability than that mediated by soluble heparin. 
Discussion 
Our  results  demonstrate  that  three  different  syndecans 
and glypican can promote the binding and activation of a 
specific kinase receptor form, i.e., the IIIc splice variant of 
the FGFR1, by a specific member of the FGF family, i.e., 
bFGF (FGF2), when expressed with the FGFR1 as core- 
ceptor pairs in transfectant K562 cells. All the forms that 
were  tested  boost  the  expression  of  cell-surface  HS  in 
these hematopoietic cells, facilitating the saturation of the 
receptor with growth factor and increasing the sensitivity 
of the cells to low doses of the growth factor that inhibit 
their erythroid differentiation, We conclude that cell-sur- 
face PGs can function as partners for the tyrosine kinases 
in a dual FGFR system, and that several different forms of 
this category of cell-surface components can provide the 
source of HS that is required for effective FGF-FGFR bind- 
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Figure 9.  Effect of bFGF on GpA expression in K562 cells. The 
various K562 cell populations were cultured for 72 h  in serum- 
free medium  supplemented  with BSA, transferrin,  and  insulin. 
After exposure  to the indicated concentrations of bFGF for an 
other 72 h  in this medium, the cell-surface GpA expression was 
measured  by  quantitative  immunofluorocytometry.  The  dis- 
played  relative mean  fluorescence intensity  values were  calcu- 
lated  as  indicated  in  Materials  and  Methods.  Receptor-trans- 
fected  cell  populations  (a)  responded  with  a  dose-dependent 
decrease in GpA expression. At the maximal concentration of 10 
ng/ml of bFGF, the GpA was reduced by 60-70%  in all transfec- 
tants. PG-transfected clones, however, responded at significantly 
lower bFGF concentrations than R-0 and R-anti-Syn4 cells, e.g., 
at bFGF concentrations as low as 0.5 ng/ml R-Glyp still showed a 
27%  suppression,  and R-anti-Syn4 cells showed only a 9%  sup- 
pression.  Chlorate-treated  R  cells (b)  were nearly unresponsive 
ing interactions. A low incidence of active HS sequences in 
these PGs may be compensated by their membrane anchor- 
age and concentration at the cell surface. 
K562 Cells as a Model  for Studying CeU-surface HS 
K562 cells were selected for these studies because a survey 
of a large panel of cells with the HS-specific mAbs 10E4 
and 3G10 had indicated that these cells were able to syn- 
thesize authentic HS, a minimal requirement to potentially 
support bFGF-receptor interactions, but in low and possi- 
bly insufficient amounts to support these interactions effi- 
ciently.  The  aim was  to  test whether  transfections  with 
cDNAs coding for cell-surface PGs could compensate for 
this  relative  HS  deficiency.  The  results  show  that  after 
these  transfections,  K562 cells are capable of expressing 
~5-10-fold higher levels of cell-surface HS, and that the 
endogenous and transfectant cell-surface PGs that account 
for this HS can be fractionated in distinctive charge and 
size classes that result from the intrinsic variability of the 
posttranslational modifications of these proteins. Compar- 
ative quantitative immunocytofluorometry indicated  that 
the HS expression in the K562 transfectants reached simi- 
lar levels as in human lung fibroblasts (not shown), sug- 
gesting  that  these  transfectants  provide relevant models 
for the display of cell-surface HS in constitutive high ex- 
pressors. It may be significant, however, that the gain of 
HS in these cells is more pronounced for the PG fractions 
that elute early from MonoQ (substituted with fewer and 
less sulfated chains)  than for those that elute later in the 
salt gradient (substituted with more and more highly sul- 
fated chains) (Fig. 4). Together with the reduced levels of 
HS glycanation of the endogenous syndecan-4 in the trans- 
fectants, these results suggest that in K562 cells, individual 
core proteins compete with each other for a  limiting HS 
glycanation  machinery,  and  that  in  high  expressors,  a 
smaller proportion of the PGs therefore reaches the most 
extensive  levels  of substitution  and  modification.  These 
findings are reminiscent of results obtained for the synthe- 
sis of antithrombin Ill-binding HS sequences in transfec- 
tant endothelial and fibroblastic cells, where several con- 
secutive transductions  of a  syndecan-4 expression vector 
progressively enhanced the production of core protein and 
total HS in these cells, but reduced the levels of antithrom- 
bin  Ill-binding  HS present  on transfectant  and  endoge- 
nous PG (Shworak et al., 1994). This suggests that the pro- 
duction of defined HS sequences can be saturated and that 
the  specific  activities  of the  PGs  in  terms  of these  se- 
quences depend at least in part on the core protein expres- 
sion levels. In the K562 PG transfectants, the transfectant 
cores drive the synthesis of ~90%  of the cell-surface HS, 
but these expression levels still appear compatible with the 
production of fully modified forms of PG and the produc- 
to bFGF, but the effect of bFGF could be restored with exoge- 
nous heparin (added at 100 ng/ml). Exposure of the wild-type or 
the  non-receptor-transfected  cell  populations  (c)  to  bFGF  in 
combination with or without heparin did not result in significant 
changes in GpA mean fluorescence intensity. Treatment of K562 
cells with the phorbol ester PMA (2 nM, over 72 h) induced an 
80% loss of GpA expression (shown only for wild-type cells in c). 
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Figure 10, Coimmobilized HSPG increases the affinity of bFGF 
for the eetodomain of FGFR1. Plasmids coding for COOH-ter- 
minal 6xHis-tailed forms of  the ectodomain of  FGFR1 (FGFRle) 
and syndecan-4  (Syn4e) were expressed in K562 cells. These 
6xHis tags bind with high affinity (K  d = 10  -t3) to Nidoaded beads 
(a).  Binding  of radiolabeled  bFGF  to  Ni-NTA=immobilized 
FGFRte in the presence or absence of Syn4e, trypsinized Syn4e 
(which lacks the 6xHis tag and therefore can not bind to the Ni- 
NTA resin), or heparin was measured at varying concentrations 
of growth factor (b). The affinity of the binding was calculated 
from the specifically bound  versus  free radiolabel  at various 
bFGF concentrations. The data are depicted as Scatchard plots. 
The concentrations of FGFRle and Syn4e used were such that 
the maximal number of bFGF-binding  rites provided by each 
oamponent individually (as determined from separate binding ex- 
periments) were identical. 
tion of the sequences required for bFGF binding and acti- 
vation. It is conceivable, however, that similar transfec- 
tions in cells that express large near-saturating amounts of 
endogenous HSPG could have adverse effects on the syn- 
thesis or colinearity of the sequences that are required for 
bFGF activation, and that this competition might explain 
how the expression of syndecan-t in 3T3 cells suppresses 
the growth response of these cells to bFGF (Mali et al., 
1993.). 
Facilitation of bFGF-Receptor Binding by 
Cell-surface HS 
The effects of chlorate on the binding of bFGF to R trans- 
fectants and.of heparin on chlorate-treated R transfectants 
were consistent with the observations of several other in- 
vestigators, suggesting a clear HS-dependency of the spe- 
dfic binding of bFGF to FGFRI(IIIc) and indicating that 
K562 cells were able to produce the HS sequences that are 
required for the stimulation of this binding. Heparin, how- 
ever, also enhanced the levels of specific bFGF binding in 
R-0 cells that were not treated with chlorate, indicating 
lack of receptor saturation in these cells despite normally 
saturating concentrations of added growth factor, possibly 
caused by PG receptor imbalances in these receptor-over- 
expressing cells. The saturation of the receptor in the R-PG 
transfectants  confirms  this  interpretation  and  indicates 
that all the different cell-surface PGs tested can comple- 
ment for the relative HS deficiency of these cells. Reduced 
levels of receptor saturation in R-anti-syndecan-4 transfec- 
tants in comparison to R-0 cells support the contention 
that  cell-surface PGs  contribute  to  receptor binding  in 
K562 cells, in apparent discrepancy with previous sugges- 
tions that these forms are inactive or even inhibitory in 
this respect (Aviezer et al., 1994a). Distinctive PG require- 
ments  for activation of the  receptor in  c/s-  and  trans- 
modes, or unique activities of the PGs in these cells, could 
account for this discrepancy. 
Our cell-free assay demonstrates that bFGF binds to the 
ectodomain of the two-Ig domain form of human FGFR1 
in the absence of heparin, and that heparin moderately en- 
hances the affinity of this binding interaction, which agrees 
with  the  results  reported by several other investigators 
with similar constructs (Kiefer et al., 1991; Bergonzoni et 
al., 1992; Roghani et al., 1994). In this assay, a syndecan 
ectodomain made by K562 cells that could be coimmobi- 
lized with receptor proved to be an effective strengthener 
~f the binding interaction, whereas the same ectodomain 
provided in equimolar amounts, but in soluble form, had 
no detectable activity. The failure of these soluble ectodo- 
mains is in agreement with previous binding results ob- 
tained for receptor-reporter fusion proteins and soluble 
cell-surface PG in cell-free assays (Aviezer et al., 1994a) 
and for the activation of receptor in HS-deficient cells by 
exogenously added PG (Aviezer et al., t994b), whereby 
several of the cell-surface PGs that were studied here were 
proven to be ineffective. All together, these findings sug- 
gest that cell-surface PGs are not intrinsically ineffective, 
but that membrane-imbedded and solubilized forms of the 
PGs  from a  particular cell differ in  their  activities on 
bFGF-receptor binding in that the former lead to higher 
effective concentrations of reactants with higher apparent 
binding affinities as a result. 
The results from the affinity cross-linking experiments 
are also consistent with a role for cell-surface HS in the re- 
ceptor-ligand  interaction.  They show  specific receptor 
binding in R cells and an increase in receptor--cross-linked 
tz~I-bFGF for the R-O and chlorate-treated R-PG cell pop- 
ulations upon the addition of heparin, consistent with the 
stimulatory effect of heparin on receptor occupancy in 
these cells. Somewhat surprisingly, since heparin did not 
promote or decrease receptor occupancy in R-PG trans- 
The  Journal  of  Cetl Biology,  Volume 133, 1996  4t4 fectants,  heparin  very  consistently  decreased  the cross- 
linking efficiency in all R-PG cells.  This difference .in re- 
ceptor-=ligand cross-linking efficiency between PG-mediated 
and (in the presence of a large excess of heparin) probably 
heparin-mediated receptor-ligand complexes suggests the 
formation of distinctive receptor--ligand  complexes in the 
two situations.  Cross-linking  likely  involves sites within 
the bFGF-receptor complex other than those directly in- 
volved in the binding interaction, and depends on the con- 
figuration of the  complex, the realized  approximations, 
and the stability of the complex. Conformational changes 
induced by exogenous heparin, but not by HS, that may be 
irrelevant for binding might disturb bFGF cross-linking. 
The finding that ternary complexes mediated by surface- 
immobilized ectodomains are more stable than heparin- 
mediated complexes might also be relevant and relate to 
the reduction in FGFR-FGF cross-links in the presence of 
heparin.  The  observation  at  least  suggests  that  exoge- 
nously added heparin does not exactly reproduce the pro- 
cess of PG-mediated binding and ¢,annot be used as the 
sole model to define .the molecular requirements for re- 
ceptor occupancy by growth factor and activation. 
Receptor Activation by CeU-surface HS 
The fact that K562 cells that expressed high levels of cell- 
surface HS, (R-PG cells) responded more dearly ~o low 
bFGF concentrations than low expressors, (R4) and R-anti- 
Syn4 cells) further supports the contention that, at tow 
doses of growth factor, {igand-induced FGFR stimulation 
and signaling depend on the availability of sufficient and 
appropriate sources of HS at the cell surface (Roghani et 
al., 1994). Our data show that :several different cell-surface 
PGs originating from separate molecular families are able 
to provide this source, at least .for the bFGF-FGFR1 inter- 
action, in cells ~vith the appropriate HS~synthesizing ma- 
chinery, and when expressed at the cell surface of ~he re- 
ceptor-expressing cells. Relatively tow specific activities of 
the cell surface PGs with respect to the fostering ,of recep- 
tor-growth  factor interactions  may be  compensated  by 
this membrane association, essentially limiting the activity 
of these PG-s to the c/s mode. Considering the relative inef- 
Iectiveness of the soluble PG ectodomains as promoters of 
the bFGF--receptor interaction, it may be significant that 
all syndecans have conserved a putative protease cleavage 
site in their ectodomain, and that glypicans are tinked to 
the cell surface by phospholipase-susceptible bonds. Syn- 
decan shedding is known to occur, at least under in vitro 
conditions, and phospholipase D  activities that release sol- 
uble bFGF--HSPG complexes have recently been identi- 
fied in HeLa cell and bone marrow stromal cell cultures 
(Metz et al., 1994). From our results, we would predict that 
at low concentrations of growth factor, protease- and li- 
pase-induced sheddings of the cell~sufface P,Gs will lead to 
a  dilution of the reactants,  dissociation of the recePtor 
complexes, and downregulation of the signaling pathway, 
unless other PGs with possibly unique trans-activation  po- 
tentials, such as ~he pedecan synthesized by cultured fetal 
lung fibroblasts (A~/iezer  et al.,  1994b), can compensate 
for this ]oss. This leads to the speculation that PG ~hedding 
may provide means for,acute regulation of c/s-activated hep- 
arm-dependent pathways, next to possibly slower regula- 
tions via controls on the synthesis of the core proteins and 
the required HS sequences. 
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